Medical device giant Medtronic launches its Resolute Integrity drug-eluting coronary stents on the Japanese market and opens its 1st research & development facility in China.

Medtronic's Resolute Integrity

Medical device giant Medtronic (NYSE:MDT) is making new moves in Asia, launching commercial sales of its Resolute Integrity stent on the Japanese market and announcing the 1st research & development facility in China.

The Resolute Integrity drug-eluting stent, which won Japanese approval earlier this year with indicated to treat coronary artery disease, made its way onto Japan's market, the world's 2nd largest for medical devices.